Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver | 110 | 2020 | 484 | 8.630 |
Why?
|
Hepatitis C, Chronic | 63 | 2015 | 77 | 8.190 |
Why?
|
Heme | 55 | 2019 | 61 | 6.220 |
Why?
|
Iron | 40 | 2019 | 116 | 5.610 |
Why?
|
Hepacivirus | 33 | 2020 | 39 | 5.310 |
Why?
|
Antiviral Agents | 48 | 2015 | 108 | 5.170 |
Why?
|
Heme Oxygenase (Decyclizing) | 41 | 2013 | 42 | 4.940 |
Why?
|
Hepatitis C | 26 | 2020 | 42 | 4.740 |
Why?
|
Heme Oxygenase-1 | 28 | 2016 | 33 | 4.560 |
Why?
|
Porphyrias | 27 | 2021 | 27 | 4.550 |
Why?
|
Porphyria, Acute Intermittent | 14 | 2021 | 16 | 4.020 |
Why?
|
Interferon-alpha | 46 | 2013 | 70 | 3.940 |
Why?
|
Porphyria Cutanea Tarda | 13 | 2020 | 15 | 3.810 |
Why?
|
Liver Cirrhosis | 45 | 2019 | 81 | 3.430 |
Why?
|
Carcinoma, Hepatocellular | 22 | 2019 | 60 | 3.180 |
Why?
|
MicroRNAs | 11 | 2018 | 180 | 2.840 |
Why?
|
5-Aminolevulinate Synthetase | 25 | 2019 | 26 | 2.840 |
Why?
|
RNA, Messenger | 31 | 2019 | 508 | 2.800 |
Why?
|
Hepatocytes | 13 | 2018 | 76 | 2.740 |
Why?
|
Humans | 263 | 2021 | 32114 | 2.740 |
Why?
|
Porphyrias, Hepatic | 11 | 2021 | 12 | 2.710 |
Why?
|
Liver Neoplasms | 23 | 2019 | 155 | 2.590 |
Why?
|
Liver Transplantation | 13 | 2019 | 179 | 2.540 |
Why?
|
Polyethylene Glycols | 31 | 2013 | 64 | 2.290 |
Why?
|
Liver Diseases | 23 | 2017 | 70 | 2.220 |
Why?
|
Porphyrins | 25 | 2019 | 29 | 2.210 |
Why?
|
Ribavirin | 26 | 2011 | 28 | 2.140 |
Why?
|
Gene Expression Regulation, Enzymologic | 14 | 2012 | 80 | 2.100 |
Why?
|
Protoporphyria, Erythropoietic | 10 | 2020 | 11 | 2.010 |
Why?
|
Fanconi Anemia Complementation Group Proteins | 9 | 2012 | 9 | 1.950 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 9 | 2012 | 10 | 1.950 |
Why?
|
Metalloporphyrins | 12 | 2009 | 16 | 1.870 |
Why?
|
Hepatitis, Autoimmune | 6 | 2015 | 7 | 1.860 |
Why?
|
Membrane Proteins | 18 | 2016 | 256 | 1.860 |
Why?
|
Male | 152 | 2020 | 19217 | 1.850 |
Why?
|
Mitochondria | 7 | 2019 | 187 | 1.830 |
Why?
|
Middle Aged | 119 | 2019 | 11839 | 1.720 |
Why?
|
Adult | 96 | 2021 | 9380 | 1.680 |
Why?
|
Female | 132 | 2020 | 20015 | 1.620 |
Why?
|
Animals | 92 | 2019 | 7542 | 1.580 |
Why?
|
Protoporphyrins | 15 | 2019 | 16 | 1.480 |
Why?
|
Mutation | 18 | 2020 | 489 | 1.470 |
Why?
|
Histocompatibility Antigens Class I | 11 | 2008 | 59 | 1.470 |
Why?
|
Viral Nonstructural Proteins | 4 | 2011 | 5 | 1.420 |
Why?
|
Hemochromatosis | 16 | 2010 | 70 | 1.420 |
Why?
|
Cytokines | 6 | 2018 | 256 | 1.370 |
Why?
|
Dietary Supplements | 7 | 2019 | 185 | 1.300 |
Why?
|
Fatty Liver | 10 | 2011 | 66 | 1.250 |
Why?
|
Coproporphyria, Hereditary | 3 | 2019 | 4 | 1.220 |
Why?
|
Recombinant Proteins | 43 | 2017 | 247 | 1.200 |
Why?
|
Chick Embryo | 43 | 2003 | 74 | 1.160 |
Why?
|
Hepatitis | 4 | 2017 | 8 | 1.150 |
Why?
|
Polymorphism, Genetic | 9 | 2016 | 184 | 1.100 |
Why?
|
Tumor Necrosis Factor-alpha | 4 | 2016 | 210 | 1.070 |
Why?
|
Porphobilinogen Synthase | 9 | 2019 | 10 | 1.060 |
Why?
|
Prognosis | 22 | 2018 | 1497 | 1.050 |
Why?
|
Hepatitis B, Chronic | 4 | 2012 | 7 | 1.020 |
Why?
|
Transfection | 18 | 2017 | 191 | 0.950 |
Why?
|
Cytochrome P-450 Enzyme System | 20 | 2011 | 27 | 0.940 |
Why?
|
Cells, Cultured | 37 | 2017 | 834 | 0.940 |
Why?
|
Host-Pathogen Interactions | 3 | 2014 | 24 | 0.930 |
Why?
|
Acute Disease | 12 | 2017 | 253 | 0.920 |
Why?
|
Aged | 52 | 2019 | 10314 | 0.910 |
Why?
|
RNA, Viral | 17 | 2015 | 48 | 0.880 |
Why?
|
Drugs, Chinese Herbal | 3 | 2014 | 7 | 0.880 |
Why?
|
Viral Proteins | 4 | 2013 | 35 | 0.860 |
Why?
|
Prospective Studies | 29 | 2019 | 2283 | 0.860 |
Why?
|
Hyperlipidemias | 3 | 2014 | 54 | 0.850 |
Why?
|
Iron Metabolism Disorders | 2 | 2012 | 2 | 0.840 |
Why?
|
Cell Line, Tumor | 15 | 2017 | 726 | 0.830 |
Why?
|
Up-Regulation | 11 | 2017 | 189 | 0.820 |
Why?
|
Mitochondrial Proteins | 3 | 2018 | 66 | 0.820 |
Why?
|
Sex Factors | 3 | 2019 | 667 | 0.800 |
Why?
|
Cholestasis | 7 | 2019 | 18 | 0.800 |
Why?
|
Porphyria, Variegate | 2 | 2014 | 2 | 0.800 |
Why?
|
Promoter Regions, Genetic | 12 | 2011 | 208 | 0.790 |
Why?
|
Phlebotomy | 9 | 2017 | 16 | 0.780 |
Why?
|
Interferons | 8 | 2015 | 17 | 0.770 |
Why?
|
Medicine, Chinese Traditional | 2 | 2012 | 3 | 0.770 |
Why?
|
Oxidative Stress | 11 | 2019 | 231 | 0.760 |
Why?
|
Silymarin | 4 | 2011 | 36 | 0.760 |
Why?
|
Leukocytes, Mononuclear | 2 | 2019 | 56 | 0.760 |
Why?
|
Iron Overload | 6 | 2010 | 38 | 0.750 |
Why?
|
Hepatitis B | 4 | 2014 | 17 | 0.740 |
Why?
|
Down-Regulation | 7 | 2014 | 142 | 0.730 |
Why?
|
Energy Metabolism | 3 | 2019 | 147 | 0.730 |
Why?
|
Drug Hypersensitivity | 2 | 2017 | 9 | 0.730 |
Why?
|
Liver Failure, Acute | 2 | 2018 | 10 | 0.720 |
Why?
|
Pulmonary Embolism | 2 | 2015 | 49 | 0.720 |
Why?
|
HLA Antigens | 7 | 2014 | 40 | 0.720 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2013 | 261 | 0.710 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 145 | 0.710 |
Why?
|
Spinal Cord | 2 | 2011 | 130 | 0.710 |
Why?
|
Pyrroles | 4 | 2013 | 55 | 0.690 |
Why?
|
Posterior Leukoencephalopathy Syndrome | 1 | 2019 | 4 | 0.690 |
Why?
|
3' Untranslated Regions | 3 | 2014 | 24 | 0.680 |
Why?
|
Porphobilinogen | 7 | 2020 | 9 | 0.680 |
Why?
|
Central Nervous System | 1 | 2019 | 43 | 0.670 |
Why?
|
Biopsy | 22 | 2019 | 259 | 0.670 |
Why?
|
Hepatitis, Viral, Human | 3 | 2015 | 6 | 0.670 |
Why?
|
Mesenteric Arteries | 1 | 2019 | 20 | 0.650 |
Why?
|
Brain | 5 | 2019 | 951 | 0.640 |
Why?
|
Alanine Transaminase | 18 | 2016 | 47 | 0.640 |
Why?
|
Rats | 28 | 2014 | 1596 | 0.630 |
Why?
|
Antioxidants | 4 | 2011 | 115 | 0.630 |
Why?
|
Genotype | 18 | 2017 | 733 | 0.630 |
Why?
|
United States | 20 | 2021 | 3976 | 0.630 |
Why?
|
Oxygen | 1 | 2019 | 142 | 0.620 |
Why?
|
Heptanoic Acids | 2 | 2009 | 29 | 0.610 |
Why?
|
Diagnosis, Differential | 10 | 2017 | 517 | 0.610 |
Why?
|
Hepatitis B virus | 3 | 2014 | 5 | 0.610 |
Why?
|
Immunologic Tests | 1 | 2017 | 4 | 0.610 |
Why?
|
Reactive Oxygen Species | 4 | 2011 | 157 | 0.610 |
Why?
|
Isoniazid | 1 | 2017 | 4 | 0.610 |
Why?
|
Autoantibodies | 3 | 2014 | 49 | 0.610 |
Why?
|
Biopsy, Needle | 7 | 2017 | 93 | 0.610 |
Why?
|
Bile Ducts | 3 | 2017 | 20 | 0.610 |
Why?
|
Virus Internalization | 2 | 2014 | 7 | 0.600 |
Why?
|
Quality of Life | 7 | 2019 | 946 | 0.600 |
Why?
|
Lymphocyte Activation | 2 | 2017 | 88 | 0.600 |
Why?
|
Treatment Outcome | 23 | 2019 | 3306 | 0.590 |
Why?
|
Disease Progression | 20 | 2019 | 594 | 0.580 |
Why?
|
Bile Duct Diseases | 1 | 2017 | 10 | 0.570 |
Why?
|
Risk Factors | 23 | 2019 | 3880 | 0.570 |
Why?
|
Time Factors | 21 | 2016 | 2151 | 0.570 |
Why?
|
Peripheral Nervous System Diseases | 2 | 2018 | 51 | 0.560 |
Why?
|
Adolescent | 14 | 2021 | 3568 | 0.560 |
Why?
|
Enzyme Induction | 21 | 2007 | 32 | 0.560 |
Why?
|
Autoimmunity | 2 | 2014 | 32 | 0.550 |
Why?
|
Glutethimide | 12 | 2005 | 12 | 0.550 |
Why?
|
Tea | 2 | 2006 | 3 | 0.540 |
Why?
|
Camellia sinensis | 2 | 2006 | 3 | 0.540 |
Why?
|
Deferoxamine | 8 | 2009 | 8 | 0.540 |
Why?
|
Patient Selection | 3 | 2014 | 276 | 0.540 |
Why?
|
Liver Failure | 3 | 2014 | 20 | 0.540 |
Why?
|
Hepatitis E | 2 | 2013 | 6 | 0.540 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2015 | 3 | 0.520 |
Why?
|
Genetic Testing | 2 | 2013 | 96 | 0.520 |
Why?
|
Ferrochelatase | 5 | 2020 | 5 | 0.520 |
Why?
|
Chronic Disease | 16 | 2013 | 406 | 0.510 |
Why?
|
Child | 8 | 2021 | 2442 | 0.500 |
Why?
|
Severity of Illness Index | 13 | 2019 | 881 | 0.500 |
Why?
|
Virus Activation | 1 | 2014 | 7 | 0.490 |
Why?
|
Thiazoles | 4 | 2013 | 27 | 0.490 |
Why?
|
Hemin | 5 | 2017 | 5 | 0.490 |
Why?
|
Viral Core Proteins | 2 | 2011 | 2 | 0.480 |
Why?
|
Aged, 80 and over | 15 | 2019 | 3990 | 0.480 |
Why?
|
Cell Respiration | 3 | 2011 | 22 | 0.480 |
Why?
|
RNA, Small Interfering | 7 | 2019 | 114 | 0.480 |
Why?
|
Gastroenterology | 1 | 2014 | 4 | 0.480 |
Why?
|
Mitochondria, Liver | 3 | 2011 | 7 | 0.480 |
Why?
|
Gene Expression Profiling | 4 | 2013 | 322 | 0.470 |
Why?
|
Rats, Sprague-Dawley | 10 | 2014 | 743 | 0.470 |
Why?
|
Plant Preparations | 4 | 2015 | 27 | 0.470 |
Why?
|
Bilirubin | 9 | 2016 | 25 | 0.470 |
Why?
|
NF-E2-Related Factor 2 | 3 | 2011 | 9 | 0.460 |
Why?
|
RNA, Untranslated | 1 | 2013 | 10 | 0.460 |
Why?
|
Tandem Mass Spectrometry | 4 | 2013 | 60 | 0.460 |
Why?
|
Hypertension, Portal | 3 | 2010 | 10 | 0.460 |
Why?
|
Practice Guidelines as Topic | 2 | 2014 | 408 | 0.450 |
Why?
|
Mixed Function Oxygenases | 7 | 1992 | 12 | 0.450 |
Why?
|
Chromatography, Liquid | 3 | 2012 | 43 | 0.440 |
Why?
|
Proteomics | 5 | 2012 | 94 | 0.440 |
Why?
|
Transcription, Genetic | 5 | 2011 | 137 | 0.430 |
Why?
|
Stress, Psychological | 1 | 2015 | 221 | 0.430 |
Why?
|
Circadian Rhythm | 1 | 2013 | 43 | 0.430 |
Why?
|
Cytoskeletal Proteins | 1 | 2013 | 15 | 0.430 |
Why?
|
Ferritins | 5 | 2015 | 47 | 0.430 |
Why?
|
Gene Expression Regulation | 8 | 2019 | 495 | 0.430 |
Why?
|
Young Adult | 10 | 2019 | 2665 | 0.430 |
Why?
|
Chickens | 11 | 2005 | 38 | 0.420 |
Why?
|
Heptanoates | 7 | 2013 | 7 | 0.420 |
Why?
|
Porphyria, Hepatoerythropoietic | 3 | 2002 | 3 | 0.420 |
Why?
|
Vimentin | 2 | 2012 | 10 | 0.420 |
Why?
|
Acetylgalactosamine | 3 | 2021 | 3 | 0.410 |
Why?
|
Pyrrolidines | 3 | 2021 | 12 | 0.410 |
Why?
|
Phenobarbital | 7 | 2019 | 7 | 0.410 |
Why?
|
Superoxide Dismutase | 2 | 2011 | 45 | 0.410 |
Why?
|
Proteome | 4 | 2013 | 39 | 0.400 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2011 | 14 | 0.390 |
Why?
|
Contractile Proteins | 1 | 2011 | 1 | 0.390 |
Why?
|
Signal Transduction | 6 | 2019 | 682 | 0.390 |
Why?
|
Case-Control Studies | 6 | 2018 | 898 | 0.390 |
Why?
|
Dose-Response Relationship, Drug | 12 | 2019 | 633 | 0.390 |
Why?
|
Serum Albumin, Bovine | 2 | 2010 | 10 | 0.390 |
Why?
|
Cell Line | 9 | 2014 | 435 | 0.390 |
Why?
|
Magnetic Resonance Imaging | 4 | 2019 | 1328 | 0.390 |
Why?
|
Brain Chemistry | 1 | 2011 | 29 | 0.390 |
Why?
|
Peptide Hydrolases | 1 | 2011 | 17 | 0.390 |
Why?
|
Gene Expression Regulation, Viral | 2 | 2009 | 11 | 0.380 |
Why?
|
Genetic Predisposition to Disease | 6 | 2019 | 835 | 0.380 |
Why?
|
Microfilament Proteins | 1 | 2011 | 31 | 0.380 |
Why?
|
Thiazolidinediones | 2 | 2002 | 47 | 0.380 |
Why?
|
Ethanol | 4 | 2011 | 189 | 0.370 |
Why?
|
Blotting, Western | 7 | 2012 | 289 | 0.370 |
Why?
|
Arsenicals | 2 | 2001 | 12 | 0.370 |
Why?
|
Plasmapheresis | 2 | 2002 | 11 | 0.370 |
Why?
|
Albumins | 2 | 2002 | 45 | 0.370 |
Why?
|
Indoles | 2 | 2013 | 56 | 0.370 |
Why?
|
Oxygen Consumption | 1 | 2011 | 154 | 0.360 |
Why?
|
Protein Processing, Post-Translational | 2 | 2009 | 78 | 0.360 |
Why?
|
Incidence | 9 | 2017 | 1199 | 0.350 |
Why?
|
Microsomes, Liver | 7 | 1995 | 10 | 0.350 |
Why?
|
Phytotherapy | 1 | 2010 | 38 | 0.350 |
Why?
|
Fatty Acids, Monounsaturated | 1 | 2009 | 9 | 0.350 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2009 | 19 | 0.350 |
Why?
|
Hypoglycemic Agents | 2 | 2002 | 181 | 0.340 |
Why?
|
Cryoglobulinemia | 4 | 2001 | 5 | 0.340 |
Why?
|
Parenteral Nutrition | 4 | 1994 | 14 | 0.340 |
Why?
|
Interleukins | 3 | 2015 | 19 | 0.330 |
Why?
|
Viral Load | 8 | 2013 | 70 | 0.330 |
Why?
|
Calcium | 4 | 2019 | 307 | 0.330 |
Why?
|
Registries | 5 | 2018 | 298 | 0.330 |
Why?
|
Postoperative Complications | 2 | 2008 | 780 | 0.330 |
Why?
|
Drug Therapy, Combination | 14 | 2011 | 288 | 0.330 |
Why?
|
Sequence Deletion | 3 | 2011 | 40 | 0.320 |
Why?
|
Base Sequence | 7 | 2010 | 252 | 0.320 |
Why?
|
Methadone | 1 | 2008 | 12 | 0.320 |
Why?
|
Genes, Reporter | 4 | 2004 | 40 | 0.320 |
Why?
|
Narcotics | 1 | 2008 | 16 | 0.320 |
Why?
|
Guillain-Barre Syndrome | 1 | 2008 | 7 | 0.320 |
Why?
|
Uroporphyrins | 8 | 2019 | 8 | 0.320 |
Why?
|
Disease Models, Animal | 7 | 2019 | 1022 | 0.310 |
Why?
|
Aminolevulinic Acid | 5 | 2020 | 9 | 0.310 |
Why?
|
Alkaline Phosphatase | 7 | 2016 | 38 | 0.310 |
Why?
|
Sural Nerve | 1 | 2008 | 28 | 0.310 |
Why?
|
Biomedical Research | 1 | 2010 | 156 | 0.310 |
Why?
|
Gastric Bypass | 1 | 2008 | 32 | 0.310 |
Why?
|
Mice | 8 | 2019 | 2484 | 0.310 |
Why?
|
Phenotype | 8 | 2021 | 632 | 0.310 |
Why?
|
Serum Albumin | 5 | 2016 | 54 | 0.300 |
Why?
|
Molecular Sequence Data | 10 | 2011 | 359 | 0.300 |
Why?
|
Urine | 1 | 2008 | 65 | 0.300 |
Why?
|
Recurrence | 7 | 2019 | 263 | 0.300 |
Why?
|
Bone Morphogenetic Protein 4 | 2 | 2017 | 13 | 0.290 |
Why?
|
Chemokine CCL2 | 2 | 2018 | 48 | 0.290 |
Why?
|
Risk Assessment | 6 | 2017 | 1429 | 0.290 |
Why?
|
Hyperbilirubinemia | 1 | 2007 | 2 | 0.290 |
Why?
|
Anxiety | 3 | 2019 | 191 | 0.290 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2007 | 4 | 0.290 |
Why?
|
Microsatellite Repeats | 1 | 2007 | 21 | 0.290 |
Why?
|
Cohort Studies | 7 | 2017 | 1817 | 0.280 |
Why?
|
T-Lymphocytes | 5 | 2011 | 124 | 0.280 |
Why?
|
Nitrilotriacetic Acid | 6 | 2009 | 7 | 0.280 |
Why?
|
Ferric Compounds | 6 | 2009 | 15 | 0.280 |
Why?
|
Follow-Up Studies | 13 | 2017 | 2265 | 0.280 |
Why?
|
Sunlight | 2 | 2017 | 17 | 0.280 |
Why?
|
Pancreatic Neoplasms | 3 | 2013 | 134 | 0.280 |
Why?
|
Simvastatin | 1 | 2006 | 25 | 0.280 |
Why?
|
Neuralgia | 2 | 2019 | 48 | 0.270 |
Why?
|
Virus Replication | 3 | 2013 | 42 | 0.270 |
Why?
|
Mice, Inbred C57BL | 4 | 2019 | 767 | 0.260 |
Why?
|
Pilot Projects | 3 | 2019 | 548 | 0.260 |
Why?
|
Genetic Diseases, X-Linked | 2 | 2017 | 7 | 0.260 |
Why?
|
Antidepressive Agents | 2 | 2010 | 74 | 0.260 |
Why?
|
Alcohol Drinking | 1 | 2008 | 255 | 0.250 |
Why?
|
Genetic Variation | 4 | 2012 | 244 | 0.250 |
Why?
|
Bile | 1 | 2005 | 7 | 0.250 |
Why?
|
Diet, Reducing | 1 | 2006 | 106 | 0.250 |
Why?
|
Adenosine Triphosphate | 2 | 2019 | 53 | 0.250 |
Why?
|
Embolism, Air | 1 | 2005 | 5 | 0.250 |
Why?
|
Antibodies, Monoclonal | 5 | 2014 | 246 | 0.250 |
Why?
|
Hepatitis, Chronic | 2 | 2011 | 2 | 0.250 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2005 | 32 | 0.240 |
Why?
|
Hepatitis, Alcoholic | 3 | 2000 | 5 | 0.240 |
Why?
|
Sodium Compounds | 3 | 2000 | 3 | 0.240 |
Why?
|
Arsenites | 3 | 2000 | 4 | 0.240 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2012 | 510 | 0.240 |
Why?
|
Interferon Type I | 2 | 2007 | 11 | 0.240 |
Why?
|
Antihypertensive Agents | 2 | 2014 | 352 | 0.230 |
Why?
|
Chromans | 2 | 2002 | 5 | 0.230 |
Why?
|
Gene Expression | 5 | 2008 | 338 | 0.230 |
Why?
|
Erythrocytes | 3 | 2015 | 48 | 0.220 |
Why?
|
Allantois | 1 | 2003 | 3 | 0.220 |
Why?
|
Hepatic Stellate Cells | 2 | 2014 | 4 | 0.220 |
Why?
|
Chorion | 1 | 2003 | 9 | 0.220 |
Why?
|
Immunohistochemistry | 4 | 2017 | 538 | 0.220 |
Why?
|
Transcription Factors | 1 | 2004 | 181 | 0.220 |
Why?
|
Heterozygote | 3 | 2002 | 59 | 0.220 |
Why?
|
Probucol | 1 | 2003 | 1 | 0.220 |
Why?
|
Prevalence | 8 | 2021 | 989 | 0.220 |
Why?
|
Retrospective Studies | 7 | 2017 | 3510 | 0.220 |
Why?
|
Sensitivity and Specificity | 5 | 2016 | 582 | 0.220 |
Why?
|
Kupffer Cells | 4 | 2018 | 10 | 0.220 |
Why?
|
Receptors, Transferrin | 1 | 2002 | 10 | 0.220 |
Why?
|
Catechin | 2 | 2013 | 5 | 0.220 |
Why?
|
Drug Administration Schedule | 5 | 2019 | 276 | 0.210 |
Why?
|
Nutritional Physiological Phenomena | 2 | 1994 | 19 | 0.210 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 263 | 0.210 |
Why?
|
Transferrin | 7 | 2010 | 33 | 0.210 |
Why?
|
Hep G2 Cells | 4 | 2019 | 26 | 0.210 |
Why?
|
Cation Transport Proteins | 2 | 2018 | 24 | 0.210 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2003 | 112 | 0.210 |
Why?
|
Immunologic Factors | 2 | 2013 | 49 | 0.210 |
Why?
|
Liver Function Tests | 4 | 2014 | 22 | 0.210 |
Why?
|
alpha 1-Antitrypsin Deficiency | 2 | 2000 | 2 | 0.210 |
Why?
|
Anti-Bacterial Agents | 2 | 2016 | 324 | 0.210 |
Why?
|
Pharmaceutical Preparations | 2 | 2017 | 36 | 0.200 |
Why?
|
Protein Binding | 3 | 2011 | 201 | 0.200 |
Why?
|
Enzyme Inhibitors | 5 | 2001 | 166 | 0.200 |
Why?
|
Half-Life | 4 | 2009 | 23 | 0.200 |
Why?
|
Oxandrolone | 2 | 1991 | 2 | 0.200 |
Why?
|
Antigens, CD | 5 | 2015 | 103 | 0.200 |
Why?
|
Mitogen-Activated Protein Kinases | 2 | 1999 | 37 | 0.200 |
Why?
|
Splanchnic Circulation | 1 | 2001 | 3 | 0.190 |
Why?
|
Pain | 3 | 2020 | 288 | 0.190 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2013 | 160 | 0.190 |
Why?
|
Antineoplastic Agents | 3 | 2017 | 608 | 0.190 |
Why?
|
Hemopexin | 3 | 1996 | 3 | 0.190 |
Why?
|
Oxidoreductases Acting on CH-CH Group Donors | 2 | 1991 | 9 | 0.190 |
Why?
|
Lymphocytes | 2 | 2018 | 57 | 0.190 |
Why?
|
Ubiquitins | 1 | 2000 | 2 | 0.190 |
Why?
|
beta-Thalassemia | 1 | 2000 | 11 | 0.190 |
Why?
|
Binding Sites | 3 | 2014 | 130 | 0.190 |
Why?
|
Dactinomycin | 4 | 2008 | 10 | 0.180 |
Why?
|
Necrosis | 2 | 2018 | 53 | 0.180 |
Why?
|
Genes, MHC Class I | 2 | 1999 | 5 | 0.180 |
Why?
|
Platelet Count | 4 | 2009 | 23 | 0.180 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2000 | 24 | 0.180 |
Why?
|
Computational Biology | 2 | 2011 | 91 | 0.180 |
Why?
|
Iron Chelating Agents | 3 | 2010 | 7 | 0.180 |
Why?
|
Oxidation-Reduction | 5 | 2019 | 268 | 0.180 |
Why?
|
Cell Proliferation | 3 | 2017 | 604 | 0.180 |
Why?
|
Cost-Benefit Analysis | 3 | 2014 | 186 | 0.180 |
Why?
|
Anti-Anxiety Agents | 1 | 1999 | 12 | 0.170 |
Why?
|
DNA | 4 | 2004 | 226 | 0.170 |
Why?
|
Uroporphyrinogen Decarboxylase | 4 | 2007 | 4 | 0.170 |
Why?
|
Tumor Cells, Cultured | 6 | 2010 | 171 | 0.170 |
Why?
|
Iron, Dietary | 1 | 2019 | 13 | 0.170 |
Why?
|
Kinetics | 7 | 1998 | 209 | 0.170 |
Why?
|
Predictive Value of Tests | 5 | 2013 | 876 | 0.170 |
Why?
|
Electron Transport | 1 | 2019 | 16 | 0.170 |
Why?
|
Virulence | 1 | 2019 | 22 | 0.170 |
Why?
|
Glutamic Acid | 2 | 2010 | 47 | 0.170 |
Why?
|
Polymerase Chain Reaction | 4 | 2006 | 198 | 0.170 |
Why?
|
Sex Distribution | 3 | 2016 | 191 | 0.170 |
Why?
|
Magnetic Field Therapy | 1 | 2019 | 17 | 0.170 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 130 | 0.170 |
Why?
|
Liver Diseases, Alcoholic | 3 | 2011 | 6 | 0.170 |
Why?
|
Blood Platelets | 1 | 2019 | 39 | 0.170 |
Why?
|
Hydroxymethylbilane Synthase | 1 | 2019 | 1 | 0.170 |
Why?
|
Intestinal Mucosa | 2 | 2002 | 71 | 0.170 |
Why?
|
Leupeptins | 2 | 2009 | 6 | 0.170 |
Why?
|
Databases, Factual | 2 | 2019 | 355 | 0.160 |
Why?
|
Calcium Channels, T-Type | 1 | 2019 | 29 | 0.160 |
Why?
|
Amides | 1 | 2019 | 18 | 0.160 |
Why?
|
Phenylephrine | 1 | 2019 | 28 | 0.160 |
Why?
|
Drug Synergism | 5 | 2013 | 66 | 0.160 |
Why?
|
Oligopeptides | 2 | 2009 | 45 | 0.160 |
Why?
|
Aspartate Aminotransferases | 7 | 2011 | 29 | 0.160 |
Why?
|
Acetylcholine | 1 | 2019 | 48 | 0.160 |
Why?
|
Age Factors | 3 | 2017 | 1189 | 0.160 |
Why?
|
Muscles | 1 | 2019 | 62 | 0.160 |
Why?
|
RNA Interference | 3 | 2008 | 76 | 0.160 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2019 | 54 | 0.160 |
Why?
|
Analgesics | 1 | 1999 | 109 | 0.160 |
Why?
|
Colon | 2 | 1999 | 51 | 0.160 |
Why?
|
Models, Animal | 2 | 2011 | 169 | 0.160 |
Why?
|
T-Lymphocytes, Cytotoxic | 4 | 2009 | 37 | 0.160 |
Why?
|
Antigens, Viral | 3 | 2011 | 21 | 0.160 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 6 | 0.160 |
Why?
|
Vasodilation | 1 | 2019 | 94 | 0.160 |
Why?
|
Ceruloplasmin | 1 | 2018 | 5 | 0.160 |
Why?
|
Chi-Square Distribution | 2 | 2017 | 297 | 0.160 |
Why?
|
Infant | 2 | 2019 | 1062 | 0.160 |
Why?
|
Genes | 1 | 2018 | 15 | 0.150 |
Why?
|
Intestines | 2 | 1999 | 61 | 0.150 |
Why?
|
Granzymes | 1 | 2017 | 6 | 0.150 |
Why?
|
alpha-Fetoproteins | 2 | 2009 | 10 | 0.150 |
Why?
|
Secondary Prevention | 2 | 2013 | 63 | 0.150 |
Why?
|
Adaptive Immunity | 1 | 2017 | 16 | 0.150 |
Why?
|
Mutagenesis, Site-Directed | 3 | 2004 | 62 | 0.150 |
Why?
|
Haptoglobins | 2 | 2015 | 4 | 0.150 |
Why?
|
Organoplatinum Compounds | 1 | 2017 | 46 | 0.150 |
Why?
|
Analysis of Variance | 3 | 2013 | 464 | 0.150 |
Why?
|
Insulin | 2 | 2018 | 367 | 0.150 |
Why?
|
Organoids | 1 | 2018 | 94 | 0.150 |
Why?
|
Multiple Chemical Sensitivity | 1 | 1997 | 1 | 0.140 |
Why?
|
Sexual Behavior | 2 | 2010 | 120 | 0.140 |
Why?
|
Inhibitor of Differentiation Protein 2 | 1 | 2017 | 5 | 0.140 |
Why?
|
Hemolysis | 2 | 2015 | 14 | 0.140 |
Why?
|
Sterol Esterase | 1 | 2016 | 1 | 0.140 |
Why?
|
Depression | 3 | 2019 | 445 | 0.140 |
Why?
|
Feasibility Studies | 1 | 2017 | 294 | 0.140 |
Why?
|
Cholangitis | 1 | 1996 | 3 | 0.140 |
Why?
|
Metabolic Diseases | 1 | 1996 | 18 | 0.140 |
Why?
|
International Cooperation | 1 | 1996 | 28 | 0.140 |
Why?
|
Congresses as Topic | 1 | 1996 | 41 | 0.140 |
Why?
|
Apoptosis | 3 | 2013 | 360 | 0.140 |
Why?
|
Transforming Growth Factor beta | 2 | 2012 | 64 | 0.140 |
Why?
|
Lipase | 1 | 2016 | 28 | 0.140 |
Why?
|
Organometallic Compounds | 2 | 1994 | 23 | 0.140 |
Why?
|
Glutathione | 3 | 2001 | 43 | 0.140 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2016 | 2 | 0.140 |
Why?
|
Enhancer Elements, Genetic | 3 | 2002 | 18 | 0.140 |
Why?
|
Jaundice, Obstructive | 1 | 2016 | 3 | 0.140 |
Why?
|
Ferrous Compounds | 2 | 1994 | 6 | 0.140 |
Why?
|
Neurons | 2 | 2011 | 410 | 0.130 |
Why?
|
Models, Biological | 4 | 2013 | 392 | 0.130 |
Why?
|
China | 2 | 2021 | 50 | 0.130 |
Why?
|
Metallothionein | 1 | 1996 | 3 | 0.130 |
Why?
|
Menopause | 1 | 2017 | 95 | 0.130 |
Why?
|
Lead Poisoning | 1 | 2015 | 3 | 0.130 |
Why?
|
Immunoglobulin G | 3 | 2013 | 122 | 0.130 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2015 | 8 | 0.130 |
Why?
|
Fibrinolysis | 1 | 2015 | 7 | 0.130 |
Why?
|
alpha-MSH | 1 | 2015 | 2 | 0.130 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 1 | 1995 | 2 | 0.130 |
Why?
|
Amino Acid Sequence | 6 | 2011 | 285 | 0.130 |
Why?
|
Erythropoietin | 1 | 2015 | 30 | 0.130 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2020 | 291 | 0.130 |
Why?
|
Isoenzymes | 3 | 1999 | 61 | 0.130 |
Why?
|
Portal System | 2 | 2011 | 13 | 0.130 |
Why?
|
Hematologic Neoplasms | 1 | 2015 | 35 | 0.130 |
Why?
|
Double-Blind Method | 4 | 2020 | 525 | 0.130 |
Why?
|
Killer Cells, Natural | 1 | 2015 | 25 | 0.130 |
Why?
|
Rats, Inbred Strains | 8 | 1992 | 45 | 0.130 |
Why?
|
Skin Diseases | 2 | 1989 | 142 | 0.120 |
Why?
|
DNA Primers | 2 | 2008 | 91 | 0.120 |
Why?
|
Fatigue | 4 | 2020 | 85 | 0.120 |
Why?
|
Kidney | 3 | 1995 | 518 | 0.120 |
Why?
|
Mifepristone | 1 | 1994 | 8 | 0.120 |
Why?
|
Anthracyclines | 1 | 2015 | 62 | 0.120 |
Why?
|
Homeostasis | 1 | 2015 | 132 | 0.120 |
Why?
|
Claudins | 1 | 2014 | 8 | 0.120 |
Why?
|
Immunoglobulins | 1 | 2014 | 15 | 0.120 |
Why?
|
Longitudinal Studies | 5 | 2019 | 770 | 0.120 |
Why?
|
Hepatitis B Vaccines | 1 | 2014 | 10 | 0.120 |
Why?
|
Databases, Genetic | 1 | 2014 | 37 | 0.120 |
Why?
|
Tangier Disease | 1 | 1994 | 5 | 0.120 |
Why?
|
B-Lymphocytes | 1 | 2015 | 74 | 0.120 |
Why?
|
Transcription Factor AP-1 | 3 | 1999 | 19 | 0.120 |
Why?
|
Autoimmune Diseases | 3 | 2013 | 48 | 0.120 |
Why?
|
Hypergammaglobulinemia | 1 | 2014 | 1 | 0.120 |
Why?
|
Methyldopa | 1 | 2014 | 1 | 0.120 |
Why?
|
Inflammation | 1 | 2018 | 530 | 0.120 |
Why?
|
Lectins | 2 | 2011 | 10 | 0.120 |
Why?
|
Nitrofurantoin | 1 | 2014 | 3 | 0.120 |
Why?
|
Hydralazine | 1 | 2014 | 7 | 0.120 |
Why?
|
Drug Costs | 1 | 2014 | 47 | 0.120 |
Why?
|
Anti-Infective Agents, Urinary | 1 | 2014 | 4 | 0.120 |
Why?
|
Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2014 | 1 | 0.120 |
Why?
|
Adipokines | 2 | 2011 | 16 | 0.120 |
Why?
|
Delayed Diagnosis | 1 | 2014 | 15 | 0.120 |
Why?
|
Cell Transdifferentiation | 1 | 2014 | 6 | 0.120 |
Why?
|
Minocycline | 1 | 2014 | 11 | 0.120 |
Why?
|
Thrombocytopenia | 3 | 2010 | 30 | 0.120 |
Why?
|
Intestinal Polyps | 1 | 1994 | 4 | 0.120 |
Why?
|
Luciferases | 3 | 2000 | 32 | 0.120 |
Why?
|
Response Elements | 3 | 2004 | 16 | 0.120 |
Why?
|
Ascites | 3 | 2009 | 16 | 0.120 |
Why?
|
Protein-Energy Malnutrition | 1 | 1994 | 4 | 0.120 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2015 | 91 | 0.120 |
Why?
|
Cobalt | 3 | 2000 | 5 | 0.120 |
Why?
|
Nutrition Disorders | 2 | 1994 | 12 | 0.120 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 153 | 0.120 |
Why?
|
Acetaminophen | 1 | 1994 | 19 | 0.120 |
Why?
|
Rectal Neoplasms | 1 | 1994 | 18 | 0.120 |
Why?
|
Models, Immunological | 1 | 2013 | 9 | 0.120 |
Why?
|
Allylisopropylacetamide | 4 | 1996 | 4 | 0.120 |
Why?
|
Lung Diseases | 1 | 1994 | 46 | 0.120 |
Why?
|
Enteral Nutrition | 1 | 1994 | 30 | 0.110 |
Why?
|
Renal Insufficiency | 1 | 1994 | 58 | 0.110 |
Why?
|
Hydrogen Peroxide | 2 | 2011 | 85 | 0.110 |
Why?
|
Thiocyanates | 1 | 1993 | 2 | 0.110 |
Why?
|
Guanidines | 1 | 1993 | 6 | 0.110 |
Why?
|
Pyruvic Acid | 2 | 2010 | 7 | 0.110 |
Why?
|
Isothiocyanates | 1 | 1993 | 7 | 0.110 |
Why?
|
Proteins | 4 | 2012 | 144 | 0.110 |
Why?
|
Computer Simulation | 1 | 2014 | 220 | 0.110 |
Why?
|
Melatonin | 1 | 2013 | 4 | 0.110 |
Why?
|
Collagen | 3 | 2009 | 225 | 0.110 |
Why?
|
Protein Kinase Inhibitors | 1 | 2013 | 85 | 0.110 |
Why?
|
Immunity, Innate | 1 | 2013 | 75 | 0.110 |
Why?
|
Gene Deletion | 2 | 2004 | 67 | 0.110 |
Why?
|
Injections, Subcutaneous | 3 | 2020 | 35 | 0.110 |
Why?
|
Epilepsy | 1 | 2014 | 82 | 0.110 |
Why?
|
Biological Transport, Active | 1 | 2013 | 8 | 0.110 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2013 | 13 | 0.110 |
Why?
|
Esophageal and Gastric Varices | 2 | 2010 | 4 | 0.110 |
Why?
|
Combined Modality Therapy | 3 | 2007 | 560 | 0.110 |
Why?
|
Interferon-beta | 1 | 2013 | 18 | 0.110 |
Why?
|
Hydrocortisone | 1 | 2013 | 57 | 0.110 |
Why?
|
Cell Nucleus | 1 | 1993 | 108 | 0.110 |
Why?
|
Early Detection of Cancer | 1 | 2013 | 93 | 0.100 |
Why?
|
Camphor | 1 | 1992 | 1 | 0.100 |
Why?
|
Monoterpenes | 1 | 1992 | 3 | 0.100 |
Why?
|
tert-Butylhydroperoxide | 1 | 2012 | 4 | 0.100 |
Why?
|
Famous Persons | 1 | 1992 | 2 | 0.100 |
Why?
|
Terpenes | 1 | 1992 | 7 | 0.100 |
Why?
|
Stroke Volume | 1 | 2015 | 348 | 0.100 |
Why?
|
Antimalarials | 1 | 2012 | 6 | 0.100 |
Why?
|
Biliverdine | 2 | 1989 | 2 | 0.100 |
Why?
|
World Health Organization | 1 | 2012 | 15 | 0.100 |
Why?
|
Fluorescent Antibody Technique | 2 | 2011 | 91 | 0.100 |
Why?
|
Nuclear Proteins | 2 | 2004 | 75 | 0.100 |
Why?
|
Hepatitis E virus | 1 | 2011 | 3 | 0.100 |
Why?
|
Serum | 1 | 2011 | 19 | 0.100 |
Why?
|
Multiple Sclerosis | 1 | 2013 | 59 | 0.100 |
Why?
|
Cell Extracts | 1 | 2011 | 2 | 0.100 |
Why?
|
Androgens | 1 | 2011 | 30 | 0.100 |
Why?
|
Cycloheximide | 2 | 2008 | 9 | 0.100 |
Why?
|
Feces | 1 | 2011 | 38 | 0.100 |
Why?
|
Nitrogen | 1 | 1991 | 10 | 0.100 |
Why?
|
Multivariate Analysis | 3 | 2009 | 684 | 0.100 |
Why?
|
Inclusion Bodies | 1 | 2011 | 2 | 0.100 |
Why?
|
Limit of Detection | 1 | 2011 | 15 | 0.100 |
Why?
|
Calibration | 1 | 2011 | 28 | 0.100 |
Why?
|
Porins | 1 | 2011 | 1 | 0.100 |
Why?
|
Protein Synthesis Inhibitors | 2 | 2008 | 11 | 0.100 |
Why?
|
Telomere | 1 | 2011 | 10 | 0.100 |
Why?
|
RNA Stability | 1 | 2011 | 4 | 0.100 |
Why?
|
Antibodies | 1 | 1991 | 52 | 0.100 |
Why?
|
Transaminases | 2 | 2020 | 10 | 0.100 |
Why?
|
Osteoarthritis | 1 | 2012 | 79 | 0.100 |
Why?
|
Demyelinating Diseases | 1 | 2011 | 10 | 0.100 |
Why?
|
Immunoprecipitation | 1 | 2011 | 33 | 0.100 |
Why?
|
Aflatoxins | 1 | 1991 | 1 | 0.100 |
Why?
|
Neoplasm Proteins | 1 | 2012 | 148 | 0.100 |
Why?
|
Rats, Transgenic | 1 | 2011 | 47 | 0.100 |
Why?
|
Mitochondrial Membranes | 1 | 2011 | 21 | 0.100 |
Why?
|
Leukopenia | 2 | 2008 | 8 | 0.100 |
Why?
|
Hemeproteins | 1 | 2011 | 1 | 0.100 |
Why?
|
Cell Death | 1 | 2011 | 77 | 0.100 |
Why?
|
Protein Transport | 1 | 2011 | 74 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2012 | 1062 | 0.100 |
Why?
|
Carcinogens | 1 | 1991 | 35 | 0.100 |
Why?
|
Diabetes Mellitus | 2 | 2007 | 412 | 0.100 |
Why?
|
Pyruvates | 1 | 2011 | 2 | 0.100 |
Why?
|
Malates | 1 | 2011 | 2 | 0.100 |
Why?
|
Protein Engineering | 1 | 2011 | 19 | 0.090 |
Why?
|
Glutamates | 1 | 2011 | 11 | 0.090 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2011 | 69 | 0.090 |
Why?
|
Motor Neurons | 1 | 2011 | 56 | 0.090 |
Why?
|
Benzoates | 1 | 2010 | 4 | 0.090 |
Why?
|
Administration, Oral | 1 | 2011 | 187 | 0.090 |
Why?
|
Stomach Diseases | 1 | 2010 | 7 | 0.090 |
Why?
|
Hemosiderosis | 1 | 1990 | 2 | 0.090 |
Why?
|
Triazoles | 1 | 2010 | 14 | 0.090 |
Why?
|
Ketoglutaric Acids | 1 | 2010 | 5 | 0.090 |
Why?
|
Succinic Acid | 1 | 2010 | 2 | 0.090 |
Why?
|
Injections, Intravenous | 2 | 2002 | 78 | 0.090 |
Why?
|
Estrogens | 1 | 2011 | 180 | 0.090 |
Why?
|
Thiophenes | 1 | 2010 | 23 | 0.090 |
Why?
|
Infusions, Intravenous | 2 | 2006 | 100 | 0.090 |
Why?
|
Gene Regulatory Networks | 1 | 2010 | 41 | 0.090 |
Why?
|
Bone Diseases, Metabolic | 1 | 1990 | 23 | 0.090 |
Why?
|
Cluster Analysis | 1 | 2010 | 125 | 0.090 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 1 | 2010 | 16 | 0.090 |
Why?
|
Choline Deficiency | 1 | 1989 | 1 | 0.090 |
Why?
|
Alcoholism | 2 | 1994 | 101 | 0.090 |
Why?
|
Zebrafish | 2 | 2019 | 23 | 0.090 |
Why?
|
Phenylurea Compounds | 1 | 2009 | 10 | 0.090 |
Why?
|
Health Surveys | 2 | 2009 | 198 | 0.090 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 2009 | 6 | 0.090 |
Why?
|
L-Lactate Dehydrogenase | 2 | 2001 | 7 | 0.090 |
Why?
|
Coffee | 1 | 2009 | 8 | 0.090 |
Why?
|
Choline | 1 | 1989 | 14 | 0.090 |
Why?
|
Protein Stability | 1 | 2009 | 25 | 0.090 |
Why?
|
Carbamates | 1 | 2009 | 15 | 0.090 |
Why?
|
Hepatitis B Core Antigens | 1 | 2009 | 1 | 0.090 |
Why?
|
Hepatitis B e Antigens | 1 | 2009 | 1 | 0.090 |
Why?
|
Ubiquitination | 1 | 2009 | 16 | 0.090 |
Why?
|
Protein Precursors | 1 | 2009 | 22 | 0.090 |
Why?
|
Acetates | 1 | 1989 | 10 | 0.090 |
Why?
|
Antipyrine | 2 | 1991 | 3 | 0.090 |
Why?
|
Sulfhydryl Compounds | 2 | 2001 | 33 | 0.090 |
Why?
|
Depressive Disorder | 1 | 2010 | 75 | 0.090 |
Why?
|
Atenolol | 1 | 1989 | 6 | 0.080 |
Why?
|
Restriction Mapping | 2 | 2004 | 14 | 0.080 |
Why?
|
Hemorrhage | 1 | 2010 | 100 | 0.080 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 1989 | 23 | 0.080 |
Why?
|
Levulinic Acids | 2 | 1987 | 2 | 0.080 |
Why?
|
Recombinant Fusion Proteins | 2 | 2000 | 105 | 0.080 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2008 | 4 | 0.080 |
Why?
|
Carboxy-Lyases | 2 | 1985 | 4 | 0.080 |
Why?
|
Directly Observed Therapy | 1 | 2008 | 1 | 0.080 |
Why?
|
Tetrazolium Salts | 1 | 2008 | 5 | 0.080 |
Why?
|
Continental Population Groups | 1 | 2010 | 237 | 0.080 |
Why?
|
Tryptophan Oxygenase | 1 | 1988 | 1 | 0.080 |
Why?
|
Chloramphenicol O-Acetyltransferase | 2 | 2000 | 3 | 0.080 |
Why?
|
Quadriplegia | 1 | 2008 | 11 | 0.080 |
Why?
|
Atrial Natriuretic Factor | 1 | 1988 | 10 | 0.080 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2008 | 1 | 0.080 |
Why?
|
Cholecystectomy | 1 | 2008 | 22 | 0.080 |
Why?
|
Chromatography, High Pressure Liquid | 4 | 1989 | 94 | 0.080 |
Why?
|
Substance Abuse, Intravenous | 1 | 2008 | 27 | 0.080 |
Why?
|
Synapses | 1 | 2009 | 83 | 0.080 |
Why?
|
Abdominal Pain | 1 | 2008 | 44 | 0.080 |
Why?
|
Herbal Medicine | 1 | 2008 | 7 | 0.080 |
Why?
|
Alleles | 3 | 2015 | 248 | 0.080 |
Why?
|
Coproporphyrins | 2 | 1998 | 2 | 0.080 |
Why?
|
Sphingosine | 1 | 2008 | 13 | 0.080 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2008 | 16 | 0.080 |
Why?
|
Lysophospholipids | 1 | 2008 | 24 | 0.080 |
Why?
|
Vitamin E | 2 | 2002 | 23 | 0.080 |
Why?
|
Nervous System Diseases | 2 | 2001 | 39 | 0.080 |
Why?
|
Hyaluronic Acid | 1 | 2008 | 52 | 0.080 |
Why?
|
Heart Failure | 1 | 1994 | 639 | 0.070 |
Why?
|
Drug Combinations | 2 | 2012 | 98 | 0.070 |
Why?
|
Phosphorylation | 2 | 2013 | 229 | 0.070 |
Why?
|
Oligonucleotides | 1 | 2007 | 30 | 0.070 |
Why?
|
Clinical Protocols | 1 | 2007 | 97 | 0.070 |
Why?
|
Bone Marrow Cells | 1 | 2008 | 123 | 0.070 |
Why?
|
Hydrocarbons, Halogenated | 1 | 1987 | 1 | 0.070 |
Why?
|
Self Administration | 1 | 2008 | 297 | 0.070 |
Why?
|
Algorithms | 1 | 2010 | 495 | 0.070 |
Why?
|
Cyclosporine | 1 | 2007 | 49 | 0.070 |
Why?
|
Splenectomy | 1 | 2007 | 21 | 0.070 |
Why?
|
Hypertension | 1 | 2014 | 960 | 0.070 |
Why?
|
Glucose-6-Phosphate Isomerase | 1 | 2006 | 1 | 0.070 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2006 | 7 | 0.070 |
Why?
|
Endothelium, Vascular | 1 | 2008 | 156 | 0.070 |
Why?
|
Altitude Sickness | 1 | 1986 | 2 | 0.070 |
Why?
|
Endothelial Cells | 1 | 2008 | 189 | 0.070 |
Why?
|
Phenelzine | 1 | 1986 | 1 | 0.070 |
Why?
|
Genomics | 1 | 2007 | 85 | 0.070 |
Why?
|
Drug Resistance, Viral | 1 | 2006 | 9 | 0.070 |
Why?
|
Hexachlorobenzene | 1 | 1986 | 1 | 0.070 |
Why?
|
Lyases | 1 | 1986 | 1 | 0.070 |
Why?
|
Chlorobenzenes | 1 | 1986 | 2 | 0.070 |
Why?
|
North America | 2 | 2013 | 32 | 0.070 |
Why?
|
Hypercholesterolemia | 1 | 2006 | 70 | 0.070 |
Why?
|
Cadmium | 2 | 1998 | 7 | 0.060 |
Why?
|
Immunoblotting | 4 | 2001 | 51 | 0.060 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 2005 | 15 | 0.060 |
Why?
|
Regression Analysis | 3 | 1997 | 293 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2007 | 240 | 0.060 |
Why?
|
Iran | 1 | 2004 | 4 | 0.060 |
Why?
|
Logistic Models | 3 | 2017 | 783 | 0.060 |
Why?
|
Cloning, Molecular | 2 | 1998 | 75 | 0.060 |
Why?
|
Leucine Zippers | 1 | 2004 | 3 | 0.060 |
Why?
|
Intestine, Small | 1 | 1985 | 40 | 0.060 |
Why?
|
Ethnic Groups | 3 | 2016 | 476 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2005 | 83 | 0.060 |
Why?
|
Acetamides | 1 | 1984 | 7 | 0.060 |
Why?
|
Templates, Genetic | 1 | 2004 | 2 | 0.060 |
Why?
|
Gene Silencing | 1 | 2004 | 48 | 0.060 |
Why?
|
Health Status | 1 | 2006 | 400 | 0.060 |
Why?
|
Weight Loss | 1 | 2008 | 480 | 0.060 |
Why?
|
beta-Galactosidase | 2 | 2001 | 20 | 0.060 |
Why?
|
Portasystemic Shunt, Surgical | 1 | 2003 | 4 | 0.060 |
Why?
|
Liver Cirrhosis, Biliary | 3 | 1997 | 7 | 0.060 |
Why?
|
Methylcholanthrene | 4 | 1988 | 6 | 0.060 |
Why?
|
Mice, Knockout | 2 | 2008 | 443 | 0.060 |
Why?
|
Lipid Metabolism | 2 | 2015 | 105 | 0.060 |
Why?
|
Proportional Hazards Models | 3 | 2010 | 753 | 0.060 |
Why?
|
Ursodeoxycholic Acid | 1 | 2002 | 4 | 0.050 |
Why?
|
Survival Rate | 3 | 2010 | 877 | 0.050 |
Why?
|
Hyperinsulinism | 1 | 2002 | 13 | 0.050 |
Why?
|
DNA, Viral | 2 | 2009 | 54 | 0.050 |
Why?
|
Child, Preschool | 2 | 2017 | 1270 | 0.050 |
Why?
|
Treatment Failure | 3 | 2009 | 162 | 0.050 |
Why?
|
Iron-Binding Proteins | 1 | 2002 | 4 | 0.050 |
Why?
|
Leptin | 1 | 2002 | 71 | 0.050 |
Why?
|
Intestinal Absorption | 1 | 2002 | 18 | 0.050 |
Why?
|
Oxidoreductases | 3 | 1991 | 26 | 0.050 |
Why?
|
Mass Spectrometry | 2 | 2012 | 102 | 0.050 |
Why?
|
Saline Solution, Hypertonic | 1 | 2001 | 3 | 0.050 |
Why?
|
Glomerulonephritis, Membranoproliferative | 1 | 2001 | 4 | 0.050 |
Why?
|
ZAP-70 Protein-Tyrosine Kinase | 1 | 2001 | 1 | 0.050 |
Why?
|
Genistein | 1 | 2001 | 15 | 0.050 |
Why?
|
Urea | 1 | 2001 | 37 | 0.050 |
Why?
|
Subcellular Fractions | 2 | 2012 | 14 | 0.050 |
Why?
|
Histocytochemistry | 2 | 2011 | 31 | 0.050 |
Why?
|
Vasculitis | 1 | 2001 | 24 | 0.050 |
Why?
|
Kidney Medulla | 1 | 2001 | 29 | 0.050 |
Why?
|
Actins | 1 | 2001 | 51 | 0.050 |
Why?
|
Hemoglobins | 1 | 2001 | 49 | 0.050 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2001 | 40 | 0.050 |
Why?
|
Protein Isoforms | 1 | 2001 | 57 | 0.050 |
Why?
|
Arthralgia | 1 | 2001 | 33 | 0.050 |
Why?
|
Methoxamine | 1 | 2001 | 1 | 0.050 |
Why?
|
Potassium Chloride | 1 | 2001 | 5 | 0.050 |
Why?
|
Triglycerides | 1 | 2002 | 230 | 0.050 |
Why?
|
NG-Nitroarginine Methyl Ester | 1 | 2001 | 18 | 0.050 |
Why?
|
Stress, Physiological | 1 | 2001 | 55 | 0.050 |
Why?
|
Nitric Oxide Synthase | 1 | 2001 | 35 | 0.050 |
Why?
|
Cell Fractionation | 2 | 2011 | 8 | 0.050 |
Why?
|
Vasoconstriction | 1 | 2001 | 43 | 0.050 |
Why?
|
Penetrance | 1 | 2021 | 4 | 0.050 |
Why?
|
Microsomes | 2 | 1995 | 13 | 0.050 |
Why?
|
Protein Conformation | 2 | 2011 | 84 | 0.050 |
Why?
|
Sequence Homology, Nucleic Acid | 2 | 1991 | 18 | 0.050 |
Why?
|
Lymphoma | 1 | 2001 | 35 | 0.050 |
Why?
|
Species Specificity | 2 | 2013 | 90 | 0.050 |
Why?
|
Biological Specimen Banks | 1 | 2020 | 8 | 0.050 |
Why?
|
Pyruvate Dehydrogenase Complex | 2 | 1991 | 18 | 0.050 |
Why?
|
Europe | 1 | 2020 | 82 | 0.050 |
Why?
|
Consensus Sequence | 1 | 2000 | 10 | 0.050 |
Why?
|
Mammals | 1 | 2000 | 12 | 0.050 |
Why?
|
Least-Squares Analysis | 1 | 2020 | 33 | 0.050 |
Why?
|
Fat Necrosis | 1 | 2000 | 1 | 0.050 |
Why?
|
Kynurenine | 2 | 1991 | 2 | 0.040 |
Why?
|
Random Allocation | 2 | 2012 | 228 | 0.040 |
Why?
|
Tryptophan | 2 | 1991 | 4 | 0.040 |
Why?
|
Epithelium | 2 | 1993 | 31 | 0.040 |
Why?
|
Nausea | 1 | 2020 | 53 | 0.040 |
Why?
|
Binding, Competitive | 1 | 1999 | 33 | 0.040 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 1999 | 17 | 0.040 |
Why?
|
Benzodiazepines | 1 | 1999 | 9 | 0.040 |
Why?
|
Acetylcysteine | 1 | 1999 | 11 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 1999 | 28 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2017 | 1542 | 0.040 |
Why?
|
Receptors, Interferon | 1 | 1999 | 2 | 0.040 |
Why?
|
Animal Feed | 1 | 2019 | 16 | 0.040 |
Why?
|
Models, Molecular | 2 | 2011 | 193 | 0.040 |
Why?
|
Fructose | 1 | 2019 | 11 | 0.040 |
Why?
|
Genes, Recessive | 1 | 1999 | 8 | 0.040 |
Why?
|
Dermatitis, Phototoxic | 1 | 2019 | 2 | 0.040 |
Why?
|
Mesentery | 1 | 1999 | 5 | 0.040 |
Why?
|
Photosensitivity Disorders | 1 | 2019 | 12 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2019 | 16 | 0.040 |
Why?
|
Somatotypes | 1 | 2019 | 1 | 0.040 |
Why?
|
DNA Mutational Analysis | 1 | 1999 | 72 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2019 | 48 | 0.040 |
Why?
|
Radiometry | 1 | 2019 | 40 | 0.040 |
Why?
|
Organ Specificity | 1 | 2019 | 81 | 0.040 |
Why?
|
Gene Knockdown Techniques | 1 | 2019 | 77 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2019 | 115 | 0.040 |
Why?
|
Mephenytoin | 2 | 1989 | 2 | 0.040 |
Why?
|
Cell Line, Transformed | 1 | 2018 | 18 | 0.040 |
Why?
|
Spleen | 1 | 1999 | 87 | 0.040 |
Why?
|
Lipofuscin | 1 | 1998 | 3 | 0.040 |
Why?
|
Mutation, Missense | 1 | 1999 | 50 | 0.040 |
Why?
|
NADPH-Ferrihemoprotein Reductase | 2 | 1990 | 2 | 0.040 |
Why?
|
Myositis | 1 | 1998 | 10 | 0.040 |
Why?
|
Chemokine CCL3 | 1 | 2018 | 5 | 0.040 |
Why?
|
Matrix Metalloproteinase 8 | 1 | 2018 | 6 | 0.040 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2018 | 9 | 0.040 |
Why?
|
Glucose Transporter Type 4 | 1 | 2018 | 9 | 0.040 |
Why?
|
Hepatitis, Animal | 1 | 1998 | 1 | 0.040 |
Why?
|
Chemokines, CXC | 1 | 1998 | 9 | 0.040 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2018 | 30 | 0.040 |
Why?
|
Piperonyl Butoxide | 3 | 1987 | 3 | 0.040 |
Why?
|
Interleukin-8 | 1 | 1998 | 26 | 0.040 |
Why?
|
Neoplastic Stem Cells | 1 | 2019 | 99 | 0.040 |
Why?
|
TATA Box | 1 | 1998 | 1 | 0.040 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 14 | 0.040 |
Why?
|
Flavonoids | 1 | 1998 | 18 | 0.040 |
Why?
|
Alcohols | 2 | 1989 | 2 | 0.040 |
Why?
|
Introns | 1 | 1998 | 39 | 0.040 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 36 | 0.040 |
Why?
|
Genetic Techniques | 1 | 1998 | 7 | 0.040 |
Why?
|
European Continental Ancestry Group | 2 | 2016 | 1166 | 0.040 |
Why?
|
Hot Temperature | 1 | 1998 | 71 | 0.040 |
Why?
|
Exons | 1 | 1998 | 52 | 0.040 |
Why?
|
ets-Domain Protein Elk-1 | 1 | 2017 | 3 | 0.040 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2017 | 4 | 0.040 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 1 | 1997 | 2 | 0.040 |
Why?
|
DNA Fragmentation | 1 | 1997 | 7 | 0.040 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 1997 | 17 | 0.040 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 1997 | 41 | 0.040 |
Why?
|
MAP Kinase Signaling System | 1 | 2017 | 61 | 0.040 |
Why?
|
Lipid Peroxidation | 1 | 1997 | 33 | 0.040 |
Why?
|
Coproporphyrinogen Oxidase | 1 | 1997 | 1 | 0.040 |
Why?
|
Interleukin-6 | 1 | 2018 | 247 | 0.040 |
Why?
|
Adjuvants, Immunologic | 1 | 1997 | 55 | 0.040 |
Why?
|
Virus Diseases | 1 | 1997 | 22 | 0.040 |
Why?
|
Spectrophotometry, Atomic | 1 | 1996 | 1 | 0.040 |
Why?
|
Syndrome | 1 | 1997 | 72 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2017 | 104 | 0.040 |
Why?
|
Early Diagnosis | 2 | 2008 | 62 | 0.040 |
Why?
|
Rats, Wistar | 2 | 2011 | 79 | 0.030 |
Why?
|
RNA | 1 | 1997 | 92 | 0.030 |
Why?
|
HLA-DR Antigens | 1 | 1996 | 8 | 0.030 |
Why?
|
Bacterial Infections | 1 | 1997 | 51 | 0.030 |
Why?
|
Disease Management | 1 | 2017 | 126 | 0.030 |
Why?
|
Jaundice | 1 | 2016 | 5 | 0.030 |
Why?
|
Cocarcinogenesis | 1 | 1996 | 2 | 0.030 |
Why?
|
Body Weight | 2 | 2009 | 310 | 0.030 |
Why?
|
Fluorometry | 1 | 2015 | 1 | 0.030 |
Why?
|
Body Mass Index | 2 | 2009 | 923 | 0.030 |
Why?
|
Idarubicin | 1 | 2015 | 7 | 0.030 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2015 | 12 | 0.030 |
Why?
|
Daunorubicin | 1 | 2015 | 27 | 0.030 |
Why?
|
Polychlorinated Biphenyls | 2 | 1986 | 7 | 0.030 |
Why?
|
Homozygote | 2 | 2010 | 58 | 0.030 |
Why?
|
Drug Implants | 1 | 2015 | 9 | 0.030 |
Why?
|
Cytochromes | 2 | 1986 | 2 | 0.030 |
Why?
|
Epitopes | 2 | 2009 | 24 | 0.030 |
Why?
|
Rheumatoid Factor | 1 | 1995 | 4 | 0.030 |
Why?
|
Cryoglobulins | 1 | 1995 | 5 | 0.030 |
Why?
|
Antibodies, Antinuclear | 1 | 1995 | 18 | 0.030 |
Why?
|
Drug Eruptions | 1 | 2015 | 9 | 0.030 |
Why?
|
Reference Values | 1 | 2015 | 246 | 0.030 |
Why?
|
Doxorubicin | 1 | 2015 | 82 | 0.030 |
Why?
|
Immunoelectrophoresis | 2 | 1985 | 2 | 0.030 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2015 | 74 | 0.030 |
Why?
|
Staining and Labeling | 1 | 1995 | 60 | 0.030 |
Why?
|
Tissue Distribution | 1 | 1995 | 61 | 0.030 |
Why?
|
Muscle, Smooth | 1 | 1995 | 68 | 0.030 |
Why?
|
Amino Acids | 2 | 1992 | 46 | 0.030 |
Why?
|
Adenomatous Polyps | 1 | 1994 | 9 | 0.030 |
Why?
|
Colonic Polyps | 1 | 1994 | 15 | 0.030 |
Why?
|
Enzyme Repression | 1 | 1994 | 1 | 0.030 |
Why?
|
Spectrophotometry | 2 | 1984 | 22 | 0.030 |
Why?
|
Myosins | 1 | 2014 | 10 | 0.030 |
Why?
|
Peroxidase | 1 | 1994 | 31 | 0.030 |
Why?
|
Colonoscopy | 1 | 1994 | 46 | 0.030 |
Why?
|
Cytoplasm | 1 | 2014 | 29 | 0.030 |
Why?
|
Diet | 2 | 1987 | 391 | 0.030 |
Why?
|
Macrophages | 1 | 1996 | 191 | 0.030 |
Why?
|
Rectal Prolapse | 1 | 1994 | 2 | 0.030 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2015 | 170 | 0.030 |
Why?
|
Rectum | 1 | 1994 | 17 | 0.030 |
Why?
|
Anal Canal | 1 | 1994 | 20 | 0.030 |
Why?
|
Cardiac Output | 2 | 1991 | 36 | 0.030 |
Why?
|
Muscle, Skeletal | 1 | 1998 | 519 | 0.030 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 2010 | 36 | 0.030 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 33 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 458 | 0.030 |
Why?
|
Nutrition Assessment | 1 | 1994 | 55 | 0.030 |
Why?
|
Benzamides | 1 | 2013 | 50 | 0.030 |
Why?
|
Tin | 1 | 1993 | 2 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2013 | 58 | 0.030 |
Why?
|
Piperazines | 1 | 2013 | 54 | 0.030 |
Why?
|
Copper | 1 | 1993 | 12 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2015 | 672 | 0.030 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2013 | 5 | 0.030 |
Why?
|
Pyrimidines | 1 | 2013 | 65 | 0.030 |
Why?
|
STAT2 Transcription Factor | 1 | 2013 | 1 | 0.030 |
Why?
|
Zinc | 1 | 1993 | 32 | 0.030 |
Why?
|
Comorbidity | 1 | 2015 | 566 | 0.030 |
Why?
|
STAT1 Transcription Factor | 1 | 2013 | 12 | 0.030 |
Why?
|
Cell Survival | 1 | 2013 | 285 | 0.030 |
Why?
|
Epithelial Cells | 1 | 1993 | 141 | 0.030 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2013 | 46 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2013 | 28 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2013 | 65 | 0.030 |
Why?
|
Liver Glycogen | 1 | 1992 | 4 | 0.030 |
Why?
|
Genetic Markers | 1 | 2013 | 124 | 0.030 |
Why?
|
Paintings | 1 | 1992 | 2 | 0.030 |
Why?
|
Oxidoreductases, N-Demethylating | 1 | 1992 | 5 | 0.030 |
Why?
|
Netherlands | 1 | 1992 | 22 | 0.030 |
Why?
|
Linkage Disequilibrium | 1 | 2013 | 185 | 0.030 |
Why?
|
History, 19th Century | 1 | 1992 | 13 | 0.030 |
Why?
|
Alcoholic Beverages | 1 | 1992 | 6 | 0.030 |
Why?
|
Space Flight | 1 | 1992 | 22 | 0.030 |
Why?
|
Trans-Activators | 1 | 2012 | 46 | 0.030 |
Why?
|
Blood Proteins | 1 | 2012 | 19 | 0.030 |
Why?
|
Bone Density | 2 | 1991 | 205 | 0.030 |
Why?
|
Fatty Liver, Alcoholic | 1 | 2011 | 1 | 0.030 |
Why?
|
Candida | 1 | 2011 | 7 | 0.030 |
Why?
|
Virus Cultivation | 1 | 2011 | 3 | 0.030 |
Why?
|
Tetanus Toxin | 1 | 2011 | 6 | 0.030 |
Why?
|
Genome, Human | 1 | 2012 | 132 | 0.030 |
Why?
|
NADH Dehydrogenase | 1 | 1991 | 4 | 0.030 |
Why?
|
Recombination, Genetic | 1 | 2011 | 22 | 0.030 |
Why?
|
Mutagenesis, Insertional | 1 | 2011 | 15 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 1991 | 14 | 0.020 |
Why?
|
Liver Circulation | 1 | 1991 | 7 | 0.020 |
Why?
|
Galactose | 1 | 1991 | 3 | 0.020 |
Why?
|
Osteocalcin | 1 | 1991 | 9 | 0.020 |
Why?
|
Hydroxyindoleacetic Acid | 1 | 1991 | 17 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2011 | 40 | 0.020 |
Why?
|
Animals, Newborn | 1 | 2011 | 114 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2011 | 137 | 0.020 |
Why?
|
Biotransformation | 1 | 1991 | 4 | 0.020 |
Why?
|
Aflatoxin B1 | 1 | 1991 | 3 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2011 | 146 | 0.020 |
Why?
|
Liver Regeneration | 1 | 2011 | 24 | 0.020 |
Why?
|
Rabbits | 1 | 1991 | 197 | 0.020 |
Why?
|
Apoproteins | 1 | 2011 | 3 | 0.020 |
Why?
|
Area Under Curve | 1 | 2011 | 93 | 0.020 |
Why?
|
Amino Acid Motifs | 1 | 2011 | 24 | 0.020 |
Why?
|
Gene Library | 1 | 1991 | 8 | 0.020 |
Why?
|
Demography | 1 | 2011 | 110 | 0.020 |
Why?
|
DNA Probes | 1 | 1991 | 19 | 0.020 |
Why?
|
Ketone Oxidoreductases | 1 | 1991 | 2 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2000 | 1428 | 0.020 |
Why?
|
Lysosomes | 1 | 1991 | 10 | 0.020 |
Why?
|
Free Radicals | 1 | 1991 | 9 | 0.020 |
Why?
|
Multienzyme Complexes | 1 | 1991 | 18 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2011 | 185 | 0.020 |
Why?
|
Ascorbic Acid | 1 | 1991 | 23 | 0.020 |
Why?
|
Bone and Bones | 1 | 1991 | 94 | 0.020 |
Why?
|
Potassium | 1 | 1991 | 40 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2010 | 39 | 0.020 |
Why?
|
Membrane Potentials | 1 | 1991 | 81 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2011 | 173 | 0.020 |
Why?
|
Chromatography, Ion Exchange | 1 | 1990 | 4 | 0.020 |
Why?
|
Chromatography | 1 | 1990 | 4 | 0.020 |
Why?
|
Chromatography, Gel | 1 | 1990 | 9 | 0.020 |
Why?
|
Safety | 1 | 2010 | 77 | 0.020 |
Why?
|
Cations | 1 | 1990 | 10 | 0.020 |
Why?
|
Hydroxyapatites | 1 | 1990 | 3 | 0.020 |
Why?
|
Blotting, Northern | 1 | 1990 | 31 | 0.020 |
Why?
|
Durapatite | 1 | 1990 | 9 | 0.020 |
Why?
|
Molecular Weight | 1 | 1990 | 41 | 0.020 |
Why?
|
Genome-Wide Association Study | 1 | 2012 | 547 | 0.020 |
Why?
|
Cause of Death | 1 | 2011 | 236 | 0.020 |
Why?
|
Creatinine | 1 | 2010 | 195 | 0.020 |
Why?
|
Cattle | 1 | 1990 | 103 | 0.020 |
Why?
|
Prothrombin | 1 | 2009 | 2 | 0.020 |
Why?
|
Drinking Behavior | 1 | 2009 | 10 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 1990 | 94 | 0.020 |
Why?
|
Polycyclic Compounds | 1 | 1989 | 1 | 0.020 |
Why?
|
Isomerism | 1 | 1989 | 7 | 0.020 |
Why?
|
Forecasting | 1 | 1990 | 143 | 0.020 |
Why?
|
Peritonitis | 1 | 2009 | 14 | 0.020 |
Why?
|
Carrier State | 1 | 2009 | 23 | 0.020 |
Why?
|
Gene Frequency | 1 | 2010 | 220 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2009 | 60 | 0.020 |
Why?
|
Metals | 1 | 1989 | 18 | 0.020 |
Why?
|
Hispanic Americans | 1 | 2016 | 940 | 0.020 |
Why?
|
Long-Term Care | 1 | 2009 | 25 | 0.020 |
Why?
|
Models, Statistical | 1 | 2010 | 175 | 0.020 |
Why?
|
Antibody Specificity | 1 | 1989 | 13 | 0.020 |
Why?
|
Succinates | 1 | 2009 | 6 | 0.020 |
Why?
|
Mitochondria, Heart | 1 | 2009 | 17 | 0.020 |
Why?
|
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2009 | 4 | 0.020 |
Why?
|
Cytochrome P-450 CYP1A2 | 2 | 1986 | 3 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2009 | 87 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2009 | 149 | 0.020 |
Why?
|
Probability | 1 | 2009 | 159 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 765 | 0.020 |
Why?
|
Age Distribution | 1 | 2009 | 206 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2009 | 65 | 0.020 |
Why?
|
Methemoglobin | 1 | 1988 | 1 | 0.020 |
Why?
|
African Americans | 1 | 2016 | 1425 | 0.020 |
Why?
|
Microchemistry | 1 | 1988 | 5 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1988 | 66 | 0.020 |
Why?
|
Radioimmunoassay | 1 | 1988 | 25 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2008 | 30 | 0.020 |
Why?
|
Procollagen | 1 | 2008 | 7 | 0.020 |
Why?
|
Cations, Divalent | 1 | 1988 | 4 | 0.020 |
Why?
|
Phenylhydrazines | 1 | 2008 | 1 | 0.020 |
Why?
|
Platelet Glycoprotein GPIb-IX Complex | 1 | 2008 | 4 | 0.020 |
Why?
|
Aldehyde-Lyases | 1 | 2008 | 5 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2010 | 429 | 0.020 |
Why?
|
Specimen Handling | 1 | 1988 | 33 | 0.020 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2008 | 11 | 0.020 |
Why?
|
Computers | 1 | 2008 | 23 | 0.020 |
Why?
|
Transduction, Genetic | 1 | 2008 | 42 | 0.020 |
Why?
|
Iron Carbonyl Compounds | 1 | 1987 | 1 | 0.020 |
Why?
|
Haplotypes | 1 | 2008 | 220 | 0.020 |
Why?
|
Glycoproteins | 1 | 2008 | 45 | 0.020 |
Why?
|
Stress, Mechanical | 1 | 2008 | 92 | 0.020 |
Why?
|
Adenoviridae | 1 | 2008 | 66 | 0.020 |
Why?
|
Anemia | 1 | 2008 | 58 | 0.020 |
Why?
|
Bone Marrow Transplantation | 1 | 2008 | 63 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2008 | 120 | 0.020 |
Why?
|
Whole-Body Irradiation | 1 | 2008 | 53 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 1989 | 301 | 0.020 |
Why?
|
Ultrasonography | 1 | 2009 | 379 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2008 | 266 | 0.020 |
Why?
|
Cytoplasmic Granules | 2 | 1998 | 7 | 0.020 |
Why?
|
Drainage | 1 | 1987 | 72 | 0.020 |
Why?
|
Polybrominated Biphenyls | 1 | 1986 | 1 | 0.020 |
Why?
|
Research Design | 1 | 2009 | 315 | 0.020 |
Why?
|
Aminopyrine N-Demethylase | 1 | 1986 | 1 | 0.020 |
Why?
|
Cytochrome b Group | 1 | 1986 | 2 | 0.020 |
Why?
|
Glucose-6-Phosphatase | 1 | 1986 | 5 | 0.020 |
Why?
|
Cytochromes b5 | 1 | 1986 | 2 | 0.020 |
Why?
|
Lipid Peroxides | 1 | 1986 | 8 | 0.020 |
Why?
|
Drug Carriers | 1 | 2006 | 21 | 0.020 |
Why?
|
Tetrapyrroles | 1 | 1986 | 1 | 0.020 |
Why?
|
Hemodynamics | 1 | 1987 | 155 | 0.020 |
Why?
|
Neutralization Tests | 1 | 2006 | 12 | 0.020 |
Why?
|
Extracellular Space | 1 | 1986 | 25 | 0.020 |
Why?
|
Microscopy, Electron | 1 | 1986 | 30 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2006 | 58 | 0.020 |
Why?
|
Immunoassay | 1 | 1985 | 16 | 0.020 |
Why?
|
Taq Polymerase | 1 | 2005 | 1 | 0.020 |
Why?
|
Dithiothreitol | 1 | 1985 | 8 | 0.020 |
Why?
|
Bone Marrow | 1 | 2005 | 70 | 0.020 |
Why?
|
Enzyme Activation | 1 | 1985 | 135 | 0.020 |
Why?
|
Complementarity Determining Regions | 1 | 2005 | 1 | 0.020 |
Why?
|
ROC Curve | 1 | 2005 | 164 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2005 | 24 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2005 | 27 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2008 | 399 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2005 | 57 | 0.020 |
Why?
|
Apoenzymes | 1 | 1984 | 2 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 1989 | 919 | 0.020 |
Why?
|
Methionine Sulfoximine | 1 | 1984 | 1 | 0.010 |
Why?
|
Phenolsulfonphthalein | 1 | 1984 | 1 | 0.010 |
Why?
|
Buthionine Sulfoximine | 1 | 1984 | 2 | 0.010 |
Why?
|
Glucuronates | 1 | 1984 | 4 | 0.010 |
Why?
|
Dithionite | 1 | 1984 | 4 | 0.010 |
Why?
|
Graft Survival | 1 | 2005 | 313 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2005 | 272 | 0.010 |
Why?
|
3T3 Cells | 1 | 2001 | 14 | 0.010 |
Why?
|
Fluoresceins | 1 | 2001 | 8 | 0.010 |
Why?
|
Spectrometry, Fluorescence | 1 | 2001 | 27 | 0.010 |
Why?
|
Light | 1 | 2000 | 24 | 0.010 |
Why?
|
HIV Infections | 1 | 2005 | 395 | 0.010 |
Why?
|
Receptor, Interferon alpha-beta | 1 | 1999 | 2 | 0.010 |
Why?
|
Epitope Mapping | 1 | 1998 | 3 | 0.010 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 1998 | 7 | 0.010 |
Why?
|
Genome, Viral | 1 | 1998 | 10 | 0.010 |
Why?
|
Sarcolemma | 1 | 1998 | 4 | 0.010 |
Why?
|
Vaccinia virus | 1 | 1998 | 14 | 0.010 |
Why?
|
Isoproterenol | 1 | 1998 | 16 | 0.010 |
Why?
|
Myoglobin | 1 | 1998 | 11 | 0.010 |
Why?
|
Fluorescence | 1 | 1998 | 20 | 0.010 |
Why?
|
Chemotactic Factors | 1 | 1998 | 4 | 0.010 |
Why?
|
Chemokine CXCL12 | 1 | 1998 | 25 | 0.010 |
Why?
|
Chemotaxis, Leukocyte | 1 | 1998 | 22 | 0.010 |
Why?
|
Neutrophils | 1 | 1998 | 106 | 0.010 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 1997 | 21 | 0.010 |
Why?
|
Myocardium | 1 | 1998 | 186 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 1998 | 226 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 1997 | 765 | 0.010 |
Why?
|
Cell Compartmentation | 1 | 1994 | 3 | 0.010 |
Why?
|
Rats, Inbred F344 | 1 | 1994 | 133 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 1998 | 475 | 0.010 |
Why?
|
Osteoblasts | 1 | 1991 | 45 | 0.010 |
Why?
|
3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 1991 | 1 | 0.010 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 9 | 0.010 |
Why?
|
T-Lymphocyte Subsets | 1 | 1991 | 23 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1990 | 52 | 0.010 |
Why?
|
Vitamin D | 1 | 1991 | 184 | 0.010 |
Why?
|
Vascular Resistance | 1 | 1987 | 31 | 0.000 |
Why?
|
Ellipticines | 1 | 1986 | 1 | 0.000 |
Why?
|
2-Acetylaminofluorene | 1 | 1986 | 7 | 0.000 |
Why?
|
Cytochrome P-450 CYP1A1 | 1 | 1984 | 6 | 0.000 |
Why?
|
Blood Pressure | 1 | 1987 | 845 | 0.000 |
Why?
|